Breast Cancer Campaign's Chief Executive, Baroness Delyth Morgan, comments on NICE decision to reject Avastin in combination with capecitabine for metastatic breast cancer.

Baroness Morgan said, “The decision by NICE to reject this drug combination further highlights the urgent need for more treatment options to prolong and improve the quality of life for people with advanced breast cancer. We look forward to hearing results from further studies, to help us understand who will benefit most from bevacizumab (Avastin).

“Access to Avastin may be possible through the Cancer Drugs Fund and we would urge clinicians and Strategic Health Authorities to use this avenue for patients who they feel may benefit from this treatment.”